Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021
Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the
“Company”), a clinical-stage biotechnology company discovering and
developing novel antiviral therapeutics, announces that management
will present at NobleCon17, Noble Capital Markets’ 17th Annual
Investor Conference on Tuesday, January 19, 2021 at 2:15 p.m.
Eastern time (11:15 a.m. Pacific time).
The live presentation will be available at
www.noblecon17.com. A high-definition video webcast of the
presentation will be available beginning January 20, 2021 on the
Investors section of the Cocrystal website here.
Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, hepatitis C viruses, coronaviruses and noroviruses.
Cocrystal employs unique structure-based technologies and Nobel
Prize-winning expertise to create first- and best-in-class
antiviral drugs. For further information about Cocrystal, please
Investor Contact:LHA Investor RelationsJody
# # #